News

Euclid Systems Names Key Leadership Hires and Announces Major Facility Expansion

Euclid Systems Corporation, a global leader in advanced orthokeratology and proactive myopia management, today announced two exceptional additions to its leadership team as well as the expansion of its manufacturing facility in Sterling, Virginia. The changes come at a time when Euclid’s next-generation of Ortho-K lens, Euclid MAX, is helping to combat the battle against the myopia epidemic, which is expected to affect approximately 5 billion people worldwide by 2050.1

Space at the Euclid facility in Sterling, Virginia, has now been expanded over 40%. Additions include larger manufacturing space, quality assurance labs, offices, and engineering/R&D space.

“With the launch of our game-changing Euclid Max Ortho-K lens this year, we have entered a very exciting time at Euclid. But our steadfast commitment to innovation is not taking a break. We’ve just expanded our manufacturing space and employee resources for the second time in three years and continue to grow our leadership team for future expansion,” said Euclid Systems CEO, Joseph Boorady. “We’re pleased to welcome Greg Endicott and Mark Mercier, who bring decades of experience, innovation, and results in fast-paced healthcare environments. Their knowledge and leadership, as well as the brick-and-mortar expansion of our facilities, help fortify Euclid’s growth as a cutting-edge world leader in myopia management technologies.”

As Chief Information Officer (CIO), Greg Endicott will lead Euclid’s strategic technology program and drive business initiatives in collaboration with global business leaders, including exploration of emerging technologies and new strategies. Previously, Mr. Endicott had a leadership role at Baxter Bioscience and was inaugural CIO of two scientific research companies. New Senior Director of Operations is Mark Mercier, a transformation specialist with decades of experience in contact lens manufacturing at Bausch+Lomb. Mr. Mercier will drive efficient methodologies throughout Euclid’s manufacturing and fulfillment.

Additional information on Euclid’s state-of-the-art manufacturing facility, and what differentiates Euclid in the industry, may be viewed in the video presentation, “Euclid – Your Partner in Myopia Management”.

To learn more visit the link.

Recent News

10/26/2026

ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies

ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …

10/26/2026

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases, today announced that Celia Economides, the Company’s current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer effective promptly after the Company’s reconvened 2026 Annual Meeting of Stockholders, if certain …

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …